Mind Cure Establishes Psychedelic Compound Research Program
Marijuana Stocks, Finance, & Investing December 8, 2020 MJ Shareholders 0
Mind Cure Establishes Psychedelic Compound Research Program " />
Mind Cure Health will be focus its psychedelics R&D on psilocybin, ketamine and ibogaine. The Company will pursue both pain-based and mental health applications.
MJ Shareholders
MJShareholders.com is the largest dedicated financial network and leading corporate communications firm serving the legal cannabis industry. Our network aims to connect public marijuana companies with these focused cannabis audiences across the US and Canada that are critical for growth: Short and long term cannabis investors Active funding sources Mainstream media Business leaders Cannabis consumers
No comments so far.
Be first to leave comment below.